Literature DB >> 25301611

Response to Comment on "Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring".

Sanaz Eftekhari1, Amene Shahrokhi2, Vera Tsintsadze3, Romain Nardou4, Corinne Brouchoud3, Magali Conesa4, Nail Burnashev3, Diana C Ferrari4, Yehezkel Ben-Ari5.   

Abstract

Bambini-Junior et al. questioned whether our treatment in two rodent models of autism has a long-lasting effect into adulthood. In response, we show that bumetanide treatment around delivery attenuates autistic behavioral features in adult offspring. Therefore, the polarity of γ-aminobutyric acid (GABA) actions during delivery exerts long-lasting priming actions after birth.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25301611     DOI： 10.1126/science.1256009

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  17 in total

1.  Impaired regulation of KCC2 phosphorylation leads to neuronal network dysfunction and neurodevelopmental pathology.

Authors:  Lucie I Pisella; Jean-Luc Gaiarsa; Diabé Diabira; Jinwei Zhang; Ilgam Khalilov; JingJing Duan; Kristopher T Kahle; Igor Medina
Journal:  Sci Signal       Date:  2019-10-15       Impact factor: 8.192

Review 2.  Is birth a critical period in the pathogenesis of autism spectrum disorders?

Authors:  Yehezkel Ben-Ari
Journal:  Nat Rev Neurosci       Date:  2015-07-08       Impact factor: 34.870

3.  Enhanced Social Dominance and Altered Neuronal Excitability in the Prefrontal Cortex of Male KCC2b Mutant Mice.

Authors:  Allison M J Anacker; Jacqueline T Moran; Sara Santarelli; C Gunnar Forsberg; Tiffany D Rogers; Gregg D Stanwood; Benjamin J Hall; Eric Delpire; Jeremy Veenstra-VanderWeele; Michael D Saxe
Journal:  Autism Res       Date:  2019-04-12       Impact factor: 5.216

4.  The Timing of the Excitatory-to-Inhibitory GABA Switch Is Regulated by the Oxytocin Receptor via KCC2.

Authors:  Marianna Leonzino; Marta Busnelli; Flavia Antonucci; Claudia Verderio; Michele Mazzanti; Bice Chini
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

5.  Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.

Authors:  E Lemonnier; N Villeneuve; S Sonie; S Serret; A Rosier; M Roue; P Brosset; M Viellard; D Bernoux; S Rondeau; S Thummler; D Ravel; Y Ben-Ari
Journal:  Transl Psychiatry       Date:  2017-03-14       Impact factor: 6.222

Review 6.  Molecular Pathology and Pharmacological Treatment of Autism Spectrum Disorder-Like Phenotypes Using Rodent Models.

Authors:  Hsiao-Ying Kuo; Fu-Chin Liu
Journal:  Front Cell Neurosci       Date:  2018-11-20       Impact factor: 5.505

7.  Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).

Authors:  Véronique Crutel; Estelle Lambert; Pierre-François Penelaud; Cristina Albarrán Severo; Joaquin Fuentes; Antoine Rosier; Amaia Hervás; Stéphane Marret; Guiomar Oliveira; Mara Parellada; Simon Kyaga; Sylvie Gouttefangeas; Marianne Bertrand; Denis Ravel; Bruno Falissard
Journal:  J Autism Dev Disord       Date:  2021-08

8.  Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures.

Authors:  Yehezkel Ben-Ari; Philippe Damier; Eric Lemonnier
Journal:  Front Cell Neurosci       Date:  2016-04-14       Impact factor: 5.505

Review 9.  Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases.

Authors:  Amteshwar Singh Jaggi; Aalamjeet Kaur; Anjana Bali; Nirmal Singh
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

10.  Oxytocin and Vasopressin, and the GABA Developmental Shift During Labor and Birth: Friends or Foes?

Authors:  Yehezkel Ben-Ari
Journal:  Front Cell Neurosci       Date:  2018-08-21       Impact factor: 5.505
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.